Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Neoadjuvant Chemotherapy Reduces the Treatment-free Interval After First-line Treatment in Patients With Advanced Ovarian Cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Long-term Survival After Surgical Treatment of Spinal Metastasis - The Predictive Role of Sex

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association of CD31 and p53 With Survival of Ovarian Cancer Patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The Influence of Cyst Emptying, Lymph Node Resection and Chemotherapy on Survival in Stage IA and IC1 Epithelial Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Postoperative mobilisation as an indicator for the quality of surgical nursing care

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Ovariecancerbehandling i Danmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND/AIM: The aim of the study was to compare platinum resistance and treatment-free interval (TFI) following treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) or primary debulking surgery (PDS) in women with advanced epithelial ovarian cancer (EOC).

PATIENTS AND METHODS: The study included patients diagnosed with primary EOC, stage IIIC or IV, between 2005 and 2013. Patients were grouped according to first-line treatment (PDS vs. NACT-IDS). Date of second-line treatment initiation was used to evaluate platinum sensitivity.

RESULTS: The study population included 521 patients, of which 371 (71%) and 150 (29%) underwent PDS and NACT-IDS, respectively. We found no difference in platinum resistance between groups. Platinum-sensitive patients treated with NACT-IDS had a shorter median TFI (372 vs. 497 days, p=0.042). Similarly, patients with no residual tumor after IDS had a shorter median TFI (280 vs. 302 days, p=0.005).

CONCLUSION: NACT-IDS may shorten the TFI after first-line platinum-based chemotherapy.

OriginalsprogEngelsk
TidsskriftAnticancer Research
Vol/bind40
Udgave nummer5
Sider (fra-til)2765-2770
Antal sider6
ISSN0250-7005
DOI
StatusUdgivet - maj 2020

Bibliografisk note

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

ID: 61424108